Literature DB >> 12516684

Risk factors and long-term follow-up of patients with the immune type of heparin-induced thrombocytopenia.

Edelgard Lindhoff-Last1, Britta Wenning, Martina Stein, Frank Gerdsen, Rupert Bauersachs, Roland Wagner.   

Abstract

Dispositional risk factors for developing the immune-type of heparin-induced thrombocytopenia (HIT) are yet unclear. This article presents a long-term follow-up of patients with HIT to define possible risk factors that may increase the risk of HIT. The clinical course of acute HIT was analyzed retrospectively in 52 patients with HIT. Thirteen patients died; 8 due to HIT. A follow-up investigation was performed in 28 of the remaining 39 patients 29 +/- 12 months after the onset of HIT, including genotyping for the factor V G1691A- and the prothrombin G20210A-mutation, measurement of antithrombin, protein C, protein S, factor VIII, and factor XII activity as well as the concentration of antiphospholipid antibodies. The results were compared to an age- and sex-matched control group. New thromboembolic events and re-exposure to heparin were also documented. No difference between patients and controls was observed concerning the factor V Leiden mutation, the prothrombin mutation, factor XII, antithrombin, protein S, or protein C deficiency and antiphospholipid antibodies. Increased factor VIII activity was found in 16 of 21 HIT patients compared to 4 of 21 controls (p=0.0005). New thromboembolic events developed in 5 patients within 9 months after HIT. One patient had been re-exposed to heparin 9 months after acute HIT without any complications. Increased factor VIII activity was frequently observed in patients in whom HIT developed. Thromboembolic complications within the first months after onset of HIT occurred often.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12516684     DOI: 10.1177/107602960200800406

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  3 in total

Review 1.  Postoperative thrombotic thrombocytopenic purpura.

Authors:  Ahmet Emre Eskazan; Deram Buyuktas; Teoman Soysal
Journal:  Surg Today       Date:  2013-12-29       Impact factor: 2.549

2.  Risk Factors in Hospitalized Patients for Heparin-Induced Thrombocytopenia by Real World Database: A New Role for Primary Hypercoagulable States.

Authors:  Jasmeet Kaur; Camelia Arsene; Sumeet Kumar Yadav; Olusola Ogundipe; Ambreen Malik; Anupam Ashutosh Sule; Geetha Krishnamoorthy
Journal:  J Hematol       Date:  2020-08-04

3.  Outcomes of Cerebral Venous Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia After the Acute Phase.

Authors:  Anita van de Munckhof; Erik Lindgren; Timothy J Kleinig; Thalia S Field; Charlotte Cordonnier; Katarzyna Krzywicka; Sven Poli; Mayte Sánchez van Kammen; Afshin Borhani-Haghighi; Robin Lemmens; Adrian Scutelnic; Alfonso Ciccone; Thomas Gattringer; Matthias Wittstock; Vanessa Dizonno; Annemie Devroye; Ahmed Elkady; Albrecht Günther; Alvaro Cervera; Annerose Mengel; Beng Lim Alvin Chew; Brian Buck; Carla Zanferrari; Carlos Garcia-Esperon; Christian Jacobi; Cristina Soriano; Dominik Michalski; Zohreh Zamani; Dylan Blacquiere; Elias Johansson; Elisa Cuadrado-Godia; Fabrice Vuillier; Felix J Bode; François Caparros; Frank Maier; Georgios Tsivgoulis; Hans D Katzberg; Jiangang Duan; Jim Burrow; Johann Pelz; Joshua Mbroh; Joyce Oen; Judith Schouten; Julian Zimmermann; Karl Ng; Katia Garambois; Marco Petruzzellis; Mariana Carvalho Dias; Masoud Ghiasian; Michele Romoli; Miguel Miranda; Miriam Wronski; Mona Skjelland; Mostafa Almasi-Dooghaee; Pauline Cuisenier; Seán Murphy; Serge Timsit; Shelagh B Coutts; Silvia Schönenberger; Simon Nagel; Sini Hiltunen; Sophie Chatterton; Thomas Cox; Thorsten Bartsch; Vahid Shaygannejad; Zahra Mirzaasgari; Saskia Middeldorp; Marcel M Levi; Johanna A Kremer Hovinga; Katarina Jood; Turgut Tatlisumak; Jukka Putaala; Mirjam R Heldner; Marcel Arnold; Diana Aguiar de Sousa; José M Ferro; Jonathan M Coutinho
Journal:  Stroke       Date:  2022-09-09       Impact factor: 10.170

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.